Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1)

Journal of Molecular and Cellular Cardiology

Volumn 53, Issue 3, 2012, Pages 392-400

  Strobel, Joachim ^a   Mieth, Maren ^a   Endreß, Beate ^a   Auge, Daniel ^a   König, Jörg ^a   Fromm, Martin F ^a   Maas, Renke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

ADMA; Asymmetric dimethylarginine; Cationic amino acid transporter 1 CAT1; L arginine; SLC7A1

Indexed keywords

AMINO ACID TRANSPORTER; ARGININE; METFORMIN; N(G),N(G) DIMETHYLARGININE;

ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; HUMAN; HUMAN CELL; IC 50; INTRACELLULAR TRANSPORT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ARGININE; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; CARDIOVASCULAR DISEASES; CATIONIC AMINO ACID TRANSPORTER 1; GENE EXPRESSION; HEK293 CELLS; HUMANS; KINESICS; METFORMIN; RISK;

EID: 84864820728     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2012.06.002     Document Type: Article

References (68)

1. Böger R.H., Sullivan L.M., Schwedhelm E., Wang T.J., Maas R., Benjamin E.J., et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119:1592-1600.
2. Böger R.H., Maas R., Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009, 60:481-487.
3. Zoccali C., Bode-Böger S., Mallamaci F., Benedetto F., Tripepi G., Malatino L., et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001, 358:2113-2117.
4. Kiechl S., Lee T., Santer P., Thompson G., Tsimikas S., Egger G., et al. Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population. Atherosclerosis 2009, 205:261-265.
5. Schulze F., Carter A.M., Schwedhelm E., Ajjan R., Maas R., von Holten R.A., et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 2010, 208:518-523.
6. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005, 97:e53-e59.
7. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
8. Schepers E., Glorieux G., Dhondt A., Leybaert L., Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009, 24:1429-1435.
9. Vallance P., Leone A., Calver A., Collier J., Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992, 20(Suppl. 12):S60-S62.
10. Ueda S., Kato S., Matsuoka H., Kimoto M., Okuda S., Morimatsu M., et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003, 92:226-233.
11. Achan V., Broadhead M., Malaki M., Whitley G., Leiper J., MacAllister R., et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459.
12. Kielstein J.T., Impraim B., Simmel S., Bode-Böger S.M., Tsikas D., Frölich J.C., et al. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004, 109:172-177.
13. Xiao H.B., Yang Z.C., Jia S.J., Li N.S., Jiang D.J., Zhang X.H., et al. Effect of asymmetric dimethylarginine on atherogenesis and erythrocyte deformability in apolipoprotein E deficient mice. Life Sci 2007, 81:1-7.
14. Jacobi J., Maas R., Cardounel A.J., Arend M., Pope A.J., Cordasic N., et al. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol 2010, 176:2559-2570.
15. Maas R. Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 2005, 10(Suppl. 1):S49-S57.
16. Vallance P., Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004, 24:1023-1030.
17. Leiper J., Nandi M., Torondel B., Murray-Rust J., Malaki M., O'Hara B., et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203.
18. Hu X.L., Atzler D., Xu X., Zhang P., Guo H.P., Lu Z.B., et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol 2011, 31:1540-1546.
19. Geldmacher F., Lüneburg N., Bernges I., Jacobi J., König J., Baldus S., et al. A global knock out of the dimethylarginine dimethylaminohydrolase 2 (DDAH2) gene in mice has no impact on aortic endothelial function and viability. Naunyn Schmiedebergs Arch Pharmacol 2011, 383:1-112. [Abstract].
20. Ogawa T., Kimoto M., Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. J Biol Chem 1990, 265:20938-20945.
21. Rodionov R.N., Murry D.J., Vaulman S.F., Stevens J.W., Lentz S.R. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem 2010, 285:5385-5391.
22. Ogawa T., Kimoto M., Sasaoka K. Purification and properties of a new enzyme, NG, NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem 1989, 264:10205-10209.
23. Tsikas D., Rode I., Becker T., Nashan B., Klempnauer J., Frölich J.C. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003, 38:1063-1064.
24. Bode-Böger S.M., Scalera F., Kielstein J.T., Martens-Lobenhoffer J., Breithardt G., Fobker M., et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol 2006, 17:1128-1134.
25. Hu X., Xu X., Zhu G., Atzler D., Kimoto M., Chen J., et al. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 2009, 120:2222-2229.
26. Closs E.I., Gräf P., Habermeier A., Cunningham J.M., Förstermann U. Human cationic amino acid transporters hCAT-1, hCAT-2A, and hCAT-2B: three related carriers with distinct transport properties. Biochemistry 1997, 36:6462-6468.
27. Teerlink T., Luo Z., Palm F., Wilcox C.S. Cellular ADMA: regulation and action. Pharmacol Res 2009, 60:448-460.
28. Closs E.I., Boissel J.P., Habermeier A., Rotmann A. Structure and function of cationic amino acid transporters (CATs). J Membr Biol 2006, 213:67-77.
29. Mann G.E., Yudilevich D.L., Sobrevia L. Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol Rev 2003, 83:183-252.
30. Devés R., Boyd C.A. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev 1998, 78:487-545.
31. White M.F., Christensen H.N. The two-way flux of cationic amino acids across the plasma membrane of mammalian cells is largely explained by a single transport system. J Biol Chem 1982, 257:10069-10080.
32. White M.F., Gazzola G.C., Christensen H.N. Cationic amino acid transport into cultured animal cells. I. Influx into cultured human fibroblasts. J Biol Chem 1982, 257:4443-4449.
33. Kim J.W., Closs E.I., Albritton L.M., Cunningham J.M. Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 1991, 352:725-728.
34. Closs E.I., Basha F.Z., Habermeier A., Förstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997, 1:65-73.
35. Perkins C.P., Mar V., Shutter J.R., del Castillo J., Danilenko D.M., Medlock E.S., et al. Anemia and perinatal death result from loss of the murine ecotropic retrovirus receptor mCAT-1. Genes Dev 1997, 11:914-925.
36. Zharikov S.I., Block E.R. Characterization of l-arginine uptake by plasma membrane vesicles isolated from cultured pulmonary artery endothelial cells. Biochim Biophys Acta 1998, 1369:173-183.
37. Greene B., Pacitti A.J., Souba W.W. Characterization of l-arginine transport by pulmonary artery endothelial cells. Am J Physiol 1993, 264:L351-L356.
38. Yang Z., Venardos K., Jones E., Morris B.J., Chin-Dusting J., Kaye D.M. Identification of a novel polymorphism in the 3'UTR of the l-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 2007, 115:1269-1274.
39. Seithel A., Eberl S., Singer K., Auge D., Heinkele G., Wolf N.B., et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos 2007, 35:779-786.
40. Mandery K., Bujok K., Schmidt I., Wex T., Treiber G., Malfertheiner P., et al. Influence of cyclooxygenase inhibitors on the function of the prostaglandin transporter organic anion-transporting polypeptide 2A1 expressed in human gastroduodenal mucosa. J Pharmacol Exp Ther 2010, 332:345-351.
41. Cui Y., König J., Buchholz J.K., Spring H., Leier I., Keppler D. Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol Pharmacol 1999, 55:929-937.
42. Maas R., Tan-Andreesen J., Schwedhelm E., Schulze F., Böger R.H. A stable-isotope based technique for the determination of dimethylarginine dimethylaminohydrolase (DDAH) activity in mouse tissue. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 851:220-228.
43. Closs E.I. Expression, regulation and function of carrier proteins for cationic amino acids. Curr Opin Nephrol Hypertens 2002, 11:99-107.
44. Dye J.F., Vause S., Johnston T., Clark P., Firth J.A., D'Souza S.W., et al. Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells. FASEB J 2004, 18:125-127.
45. Li C., Huang W., Harris M.B., Goolsby J.M., Venema R.C. Interaction of the endothelial nitric oxide synthase with the CAT-1 arginine transporter enhances NO release by a mechanism not involving arginine transport. Biochem J 2005, 386:567-574.
46. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002, 51:843-846.
47. Hingorani A.D. Polymorphisms in endothelial nitric oxide synthase and atherogenesis: John French Lecture 2000. Atherosclerosis 2001, 154:521-527.
48. Cardounel A.J., Cui H., Samouilov A., Johnson W., Kearns P., Tsai A.L., et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem 2007, 282:879-887.
49. Pollock J.S., Förstermann U., Mitchell J.A., Warner T.D., Schmidt H.H., Nakane M., et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci U S A 1991, 88:10480-10484.
50. Baydoun A.R., Emery P.W., Pearson J.D., Mann G.E. Substrate-dependent regulation of intracellular amino acid concentrations in cultured bovine aortic endothelial cells. Biochem Biophys Res Commun 1990, 173:940-948.
51. Hecker M., Mitchell J.A., Harris H.J., Katsura M., Thiemermann C., Vane J.R. Endothelial cells metabolize NG-monomethyl-l-arginine to l-citrulline and subsequently to l-arginine. Biochem Biophys Res Commun 1990, 167:1037-1043.
52. Gold M.E., Bush P.A., Ignarro L.J. Depletion of arterial l-arginine causes reversible tolerance to endothelium-dependent relaxation. Biochem Biophys Res Commun 1989, 164:714-721.
53. Bogle R.G., MacAllister R.J., Whitley G.S., Vallance P. Induction of NG-monomethyl-l-arginine uptake: a mechanism for differential inhibition of NO synthases?. Am J Physiol 1995, 269:C750-C756.
54. Xiao S., Wagner L., Mahaney J., Baylis C. Uremic levels of urea inhibit l-arginine transport in cultured endothelial cells. Am J Physiol Renal Physiol 2001, 280:F989-F995.
55. Tojo A., Welch W.J., Bremer V., Kimoto M., Kimura K., Omata M., et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int 1997, 52:1593-1601.
56. Closs E.I., Albritton L.M., Kim J.W., Cunningham J.M. Identification of a low affinity, high capacity transporter of cationic amino acids in mouse liver. J Biol Chem 1993, 268:7538-7544.
57. Bogle R.G., Baydoun A.R., Pearson J.D., Mann G.E. Regulation of l-arginine transport and nitric oxide release in superfused porcine aortic endothelial cells. J Physiol 1996, 490(Pt 1):229-241.
58. Slenzka A., Unger G., Habermeier A., Closs E.I. Removal of intracellular asymmetric dimethyl-l-arginine (ADMA) requires system y+L membrane transporter-despite significant activity of the metabolising enzyme dimethylarginine dimethylaminohydrolase (DDAH). Naunyn Schmiedebergs Arch Pharmacol 2011, 383:1-112. [Abstract].
59. Rudolph T.K., Ruempler K., Schwedhelm E., Tan-Andresen J., Riederer U., Böger R.H., et al. Acute effects of various fast-food meals on vascular function and cardiovascular disease risk markers: the Hamburg Burger Trial. Am J Clin Nutr 2007, 86:334-340.
60. Walker H.A., McGing E., Fisher I., Böger R.H., Bode-Böger S.M., Jackson G., et al. Endothelium-dependent vasodilation is independent of the plasma l-arginine/ADMA ratio in men with stable angina: lack of effect of oral l-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001, 38:499-505.
61. Wilson A.M., Harada R., Nair N., Balasubramanian N., Cooke J.P. l-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation 2007, 116:188-195.
62. Schwedhelm E., Maas R., Freese R., Jung D., Lukacs Z., Jambrecina A., et al. Pharmacokinetic and pharmacodynamic properties of oral l-citrulline and l-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol 2008, 65:51-59.
63. Schwedhelm E., Xanthakis V., Maas R., Sullivan L.M., Atzler D., Lüneburg N., et al. Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort. Clin Chem Lab Med 2011, 49:1907-1910.
64. McDonald K.K., Zharikov S., Block E.R., Kilberg M.S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the "arginine paradox". J Biol Chem 1997, 272:31213-31216.
65. Zani B.G., Bohlen H.G. Transport of extracellular l-arginine via cationic amino acid transporter is required during in vivo endothelial nitric oxide production. Am J Physiol Heart Circ Physiol 2005, 289:H1381-H1390.
66. Wu F., Cholewa B., Mattson D.L. Characterization of l-arginine transporters in rat renal inner medullary collecting duct. Am J Physiol Regul Integr Comp Physiol 2000, 278:R1506-R1512.
67. Preik-Steinhoff H., Zink S., Rösen P., Kelm M. Transport of l-arginine in arginine-deprived endothelial cells. Biochem Biophys Res Commun 1995, 213:447-453.
68. Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L. Nitric oxide synthesis requires activity of the cationic and neutral amino acid transport system y+L in human umbilical vein endothelium. Exp Physiol 2003, 88:699-710.